艾美疫苗(06660)发布公告，黄沛翘女士(黄女士)已提呈辞任本公司联席公司秘书(联席公司秘书)，自 2025年12月31日起生效。 另一位联席公司秘书刘灵女士(刘女士)近期已获联交所确认，其符合联交所证券上市规则(上市规则)第 3.28条规定担任本公司公司秘书的资格，故无需进一步豁免。于黄女士辞任后，刘女士将继续留任并担 任本公司唯一公司秘书，自2025年12月31日起生效。 黄女士于辞任联席公司秘书后，亦已根据上市规则第3.05条的规定辞任本公司授权代表(授权代表)。董 事会宣布，刘女士已获委任为授权代表，以接替黄女士，自2025年12月31日起生效。执行董事周延先生 将继续担任另一授权代表。 ...

Group 1 - The company announced the resignation of Ms. Huang Peiqiao as a co-secretary, effective from December 31, 2025 [1] - Ms. Liu Ling has been confirmed by the Stock Exchange to meet the qualifications to serve as the company secretary, thus no further exemption is required [1] - Following Ms. Huang's resignation, Ms. Liu will continue as the sole company secretary starting from December 31, 2025 [1] Group 2 - Ms. Huang has also resigned as the authorized representative according to the listing rules, effective from the same date [1] - The board has appointed Ms. Liu as the authorized representative to replace Ms. Huang, effective from December 31, 2025 [1] - Executive Director Mr. Zhou Yan will continue to serve as another authorized representative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 聯席公司秘書辭任、 委任公司秘書 及 更換授權代表 聯席公司秘書辭任 劉 靈 女 士，自2011年11月加入本公司以來 曾 擔 任 多 項 管 理 職 務，並 自2015 年11月起擔任董事會秘書 及 自2022年3月起擔任首席投資官。彼 負責管理 董 事 會 辦 公 室 及 本 公 司 投 資 管 理，主 要 負 責 本 公 司 的 對 外 信 息 披 露、投 資 者 關 係 管 理；對 內 負 責 股 權 事 務 管 理 及 企業管治 等 事 宜。 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）董 事 （「 ...

Core Insights - The biopharmaceutical sector is one of the fastest-growing areas in the pharmaceutical industry, driven by an aging population and increased public health awareness [1][5] - China's biopharmaceutical market is projected to grow from CNY 312 billion in 2019 to CNY 587.1 billion in 2024, and is expected to reach CNY 675.2 billion by 2025, with a potential to hit CNY 1.149 trillion in the next five years [1][5][6] - Innovation remains the core driver of growth in the biopharmaceutical industry, which is capital-intensive and requires significant R&D investment [1][6] Industry Definition and Classification - Biopharmaceuticals are medical products manufactured using biological methods, aimed at replicating the activity of natural substances [2][4] - They can be categorized into vaccines, blood products, biopharmaceutical drugs, diagnostic reagents, and others, with further subdivisions based on source or mechanism of action [2] Current Industry Status - The global biopharmaceutical market is expected to grow from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, with the original biopharmaceutical market projected to increase from USD 268.9 billion to USD 427.9 billion in the same period [5] - China plays a significant role in the global biopharmaceutical market, with rapid growth driven by favorable policies, increased R&D investment, and advancements in biotechnology [5][6] Industry Development Environment - Policies - The Chinese government has implemented various laws and policies to encourage biopharmaceutical R&D, including the Drug Registration Management Measures and regulations for clinical research and application of biomedical technologies [7] Competitive Landscape - The biopharmaceutical sector is recognized as a "new frontier" in the pharmaceutical industry, with major global players actively entering the market [9] - Key companies in China's biopharmaceutical industry include WuXi AppTec, Hengrui Medicine, ZhiFei Biological, BeiGene, and others, with a competitive landscape characterized by differentiated strategies [9] Future Development Trends - Market demand for biopharmaceuticals is expected to continue growing, supported by policy backing, technological advancements, and increased health awareness [10] - Domestic companies are transitioning from biosimilars to First-in-Class drugs, with examples like Hengrui Medicine's ADC drug showing superior efficacy [10][11] - Personalized medicine based on genetic testing is anticipated to become a trend, with increasing international recognition of Chinese innovative drugs [11]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | ...

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 | RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 | RMB | | 507,673,711 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- ...

Investment Rating - The industry investment rating is "Overweight" and has been maintained from the previous rating [7] Core Viewpoints - The blood purification industry in China is experiencing stable growth driven by strong supply and demand dynamics, with a market size CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [10] - The report emphasizes the potential for domestic manufacturers to replace imports, focusing on large single products, diversification, and international expansion [10] Industry Overview - The blood dialysis market is expanding, with the number of ESRD patients rapidly increasing, leading to a steady rise in dialysis demand. The number of patients receiving blood and peritoneal dialysis in China grew from 579,000 and 95,000 in 2018 to 917,000 and 153,000 in 2023, respectively [10][30] - The market for blood dialysis devices and consumables is expected to continue growing, with the blood dialysis machine market projected to reach 8.17 billion RMB by 2030 [22] Supply and Demand Dynamics - The demand side is supported by the increasing number of ESRD patients and improved medical payment capabilities, while the supply side benefits from the growing number of domestic manufacturers and supportive industry policies [10][30] - The report highlights that the domestic market is still dominated by foreign brands, but local companies are gradually increasing their market share [43][47] Investment Recommendations - The report suggests focusing on companies with strong international potential, comprehensive product matrices, and competitive single products, such as Sanwa, Baolait, Weigao Blood Purification, and others [10][30] - The report identifies three main investment themes: international expansion, product matrix improvement, and strong single product competitiveness [10] Policy Support - A series of government policies have been introduced to support the blood purification industry, including funding, tax incentives, and industry planning, which are expected to drive demand growth [55][57] - The report notes that centralized procurement of blood purification consumables has been implemented, leading to significant price reductions [57]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | 因本公 ...

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing a surge, with companies like Ai Mei Vaccine gaining significant attention due to their stable performance and innovative technologies [1] Group 1: Company Performance - Ai Mei Vaccine reported steady revenue growth for the first half of 2025, with key innovative products nearing market launch, leading to expectations of improved performance and valuation [1][2] - The company has four major innovative products entering the market, including the 13-valent pneumococcal conjugate vaccine, which has a significant market potential in China, projected to exceed RMB 20 billion by 2030 [2][3] Group 2: Product Development - Ai Mei Vaccine is advancing in the rabies vaccine sector with multiple products, including a serum-free rabies vaccine and an mRNA rabies vaccine, positioning itself as a leader in a market expected to reach RMB 20 billion by 2030 [3] - The company holds 20 vaccine candidates in development across 12 disease areas, with 23 clinical approvals and 24 clinical trials ongoing, including seven innovative vaccines [3] Group 3: Market Potential and Valuation - The 13-valent pneumococcal conjugate vaccine is anticipated to capture a significant market share, with a penetration rate in China estimated at 25.9%, compared to over 80% in the U.S., indicating substantial growth opportunities [2] - DBS Bank's report suggests that Ai Mei Vaccine's current stock price is at the lower end of its peers' valuation range, with a projected fair target price of HKD 8.3 per share by 2026, indicating a potential upside of nearly 600% [4]